Kura Oncology Inc. Expected to Post FY2016 Earnings of ($1.48) Per Share (KURA)
Kura Oncology Inc. (NASDAQ:KURA) – Equities researchers at Leerink Swann issued their FY2016 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Monday. Leerink Swann analyst J. Chang anticipates that the firm will earn ($1.48) per share for the year. Leerink Swann has a “Outperform” rating and a $15.00 price objective on the stock. Leerink Swann also issued estimates for Kura Oncology’s Q4 2016 earnings at ($0.39) EPS and FY2017 earnings at ($1.37) EPS.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, November 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.03.
A number of other equities research analysts also recently issued reports on the company. Zacks Investment Research upgraded Kura Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, October 12th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a research report on Sunday, August 14th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $14.15.
Kura Oncology (NASDAQ:KURA) opened at 5.10 on Thursday. The stock has a 50 day moving average price of $5.41 and a 200-day moving average price of $4.37. The firm’s market capitalization is $95.59 million. Kura Oncology has a 52 week low of $2.50 and a 52 week high of $8.90.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Pillar Pacific Capital Management LLC bought a new position in shares of Kura Oncology during the third quarter worth about $191,000. Minerva Advisors LLC bought a new position in shares of Kura Oncology during the second quarter worth about $977,000. Finally, Alethea Capital Management LLC bought a new position in shares of Kura Oncology during the second quarter worth about $168,000. 43.63% of the stock is currently owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.